Skip to main content
Horizons OpticalLens design

KARE: A new era in Myopia Management

At Horizons Optical, we are committed to excellence and innovation in vision care. We are proud to introduce KARE, a revolutionary solution for myopia management, developed in collaboration with the prestigious Brien Holden Vision Institute. The alliance between Horizons Optical and the Brien Holden Vision Institute has been crucial in creating an enhanced solution for myopia management based on latest scientific discoveries.

The Global Challenge of Myopia

Myopia has become a global pandemic, affecting millions of people worldwide. According to the World Health Organization (WHO), by 2050, the global prevalence of myopia is expected to reach 4.9 billion people1 . This significant increase highlights the urgent need for effective solutions to protect children’s vision and improve their quality of life.

 

KARE and HEXAVISION Technology

KARE represents an innovative approach to myopia management by utilizing HEXAVISION technology. This advanced technology divides the lens into six distinct zones, each designed specifically to provide optimal correction and management of myopia. At the core of HEXAVISION technology is Peripheral Myopic Defocus (PMD), which has been demonstrated to mitigate the progression of myopia2.

The key difference with HEXAVISION is that it manages PMD more effectively by placing the appropriate defocus in each zone based on recent scientific discoveries. As a result, KARE is expected to achieve a more optimal management of myopia compared to other lenses on the market.

Key Features of KARE:

Benefits of KARE

KARE offers multiple benefits that set it apart from other solutions on the market:

 

  • High Efficacy: HEXAVISION technology ensures continuous correction of peripheral defocus without abrupt power changes.
  • Improved Aesthetics: The invisible design of KARE offers better aesthetics compared to other solutions.
  • Easy Adaptation: Children who tested KARE lenses reported easy adaptation and high satisfaction.

 

Testing and validation

KARE is undergoing rigorous wearability and efficacy testing. In 2024, internal wearability tests were conducted at Horizons Optical facilities, where children who tested KARE lenses reported easy adaptation and high satisfaction. In 2025, a multicenter clinical trial is being conducted in Europe, Spain, to validate the efficacy of KARE in 160 myopic children.

 

Conclusion

KARE is an advanced and reliable solution for managing myopia in children, designed to offer optimal correction and management of myopia with an innovative and aesthetically pleasing approach. At Horizons Optical, we remain committed to excellence and innovation in vision care, and KARE is a testament to our dedication.

References

  1. Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, Wong TY, Naduvilath TJ, Resnikoff S. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016 May;123(5):1036-42. doi: 10.1016/j.ophtha.2016.01.006. Epub 2016 Feb 11. PMID: 26875007.
  2. Atchison DA, Charman WN. Optics of spectacle lenses intended to treat myopia progression. Optom Vis Sci. 2024 May 1;101(5):238-249. doi: 10.1097/OPX.0000000000002140. PMID: 38857035.
  3. Fabian Conrad, Thomas Naduvilath, Xiang Chen, Darrin Falk, Padmaja Sankaridurg. Contribution of peripheral refraction features to myopia progression. ARVO Poster, 2018.
  4. Whatham, Andrew & Zimmermann, Frederik & Martinez, Aldo & Delgado, Stephanie & Jara, Percy & Sankaridurg, Padmaja & Ho, Arthur. (2009). Influence of accommodation on off-axis refractive errors in myopic eyes. Journal of vision. 9. 14.1-13. 10.1167/9.3.14.
  5. Labhishetty V, Cholewiak SA, Roorda A, Banks MS. Lags and leads of accommodation in humans: Fact or fiction? J Vis. 2021 Mar;21(3):21. doi: 10.1167/jov.21.3.21. PMID: 33764384; PMCID: PMC7995353.